According to Sangamo Therapeutics 's latest financial reports the company's current revenue (TTM) is $0.17 B. In 2022 the company made a revenue of $0.11 B an increase over the years 2021 revenue that were of $0.11 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.17 B | 58.34% |
2022 | $0.11 B | 0.54% |
2021 | $0.11 B | -6.34% |
2020 | $0.11 B | 15.39% |
2019 | $0.10 B | 21.29% |
2018 | $84.45 M | 130.95% |
2017 | $36.56 M | 88.6% |
2016 | $19.38 M | -50.96% |
2015 | $39.53 M | -13.8% |
2014 | $45.87 M | 90.07% |
2013 | $24.13 M | 11.44% |
2012 | $21.65 M | 109.86% |
2011 | $10.31 M | -50.4% |
2010 | $20.8 M | -6.23% |
2009 | $22.18 M | 37.08% |
2008 | $16.18 M | 77.91% |
2007 | $9.09 M | 15.38% |
2006 | $7.88 M | 217.56% |
2005 | $2.48 M | 88.82% |
2004 | $1.31 M | -49.01% |
2003 | $2.57 M | -40.62% |
2002 | $4.34 M | -11.1% |
2001 | $4.88 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 52,683.83% | ๐บ๐ธ USA |
Amgen AMGN | $28.19 B | 15,895.96% | ๐บ๐ธ USA |
Biogen BIIB | $9.83 B | 5,481.05% | ๐บ๐ธ USA |
Dow DOW | $44.62 B | 25,220.03% | ๐บ๐ธ USA |
Gilead Sciences GILD | $27.11 B | 15,285.97% | ๐บ๐ธ USA |
Merck MRK | $60.11 B | 34,010.72% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | $1.82 B | 937.43% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $2.41 B | 1,272.75% | ๐บ๐ธ USA |